Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (отвара нови прозор)

CRASH-3 Trial Collaborators

Извор‎: Lancet 2019;394(10210):1713-23.

Индекс‎: PubMed 31623894

DOI‎: 10.1016/S0140-6736(19)32233-0

https://www.ncbi.nlm.nih.gov/pubmed/31623894 (отвара нови прозор)

Alternatives to allogeneic platelet transfusion. (отвара нови прозор)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Извор‎: Br J Haematol 2016;175(3):381-92.

Индекс‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (отвара нови прозор)

Tranexamic acid: less bleeding and less thrombosis? (отвара нови прозор)

Godier A, Roberts I, Hunt BJ.

Извор‎: Crit Care 2012;16(3):135.

Индекс‎: PubMed 22748073

DOI‎: 10.1186/cc11374

https://www.ncbi.nlm.nih.gov/pubmed/22748073 (отвара нови прозор)

Tranexamic acid for reducing mortality in emergency and urgent surgery. (отвара нови прозор)

Perel P, Ker K, Morales Uribe CH, Roberts I

Извор‎: Cochrane Database Syst Rev 2013;(1):CD010245.

Индекс‎: PubMed 23440847

DOI‎: 10.1002/14651858.CD010245.pub2

https://www.ncbi.nlm.nih.gov/pubmed/23440847 (отвара нови прозор)

The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. (отвара нови прозор)

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T; CRASH-2 collaborators.

Извор‎: Lancet 2011;377(9771):1096-101, 1101.e1-2.

Индекс‎: PubMed 21439633

DOI‎: 10.1016/S0140-6736(11)60278-X

https://www.ncbi.nlm.nih.gov/pubmed/21439633 (отвара нови прозор)

Antifibrinolytic drugs for acute traumatic injury. (отвара нови прозор)

Roberts I, Shakur H, Ker K, Coats T; CRASH‐2 Trial collaborators.

Извор‎: Cochrane Database Syst Rev 2011;(1):CD004896.

Индекс‎: PubMed 21249666

DOI‎: 10.1002/14651858.CD004896.pub3

https://www.ncbi.nlm.nih.gov/pubmed/21249666 (отвара нови прозор)

Use of tranexamic acid to reduce bleeding in burns surgery. (отвара нови прозор)

Tang YM, Chapman TW, Brooks P

Извор‎: J Plast Reconstr Aesthet Surg 2012;65(5):684-6.

Индекс‎: PubMed 21983540

DOI‎: 10.1016/j.bjps.2011.09.028

https://www.ncbi.nlm.nih.gov/pubmed/21983540 (отвара нови прозор)

Tranexamic acid reduced blood transfusions in acute burn surgery: a retrospective case-controlled trial. (отвара нови прозор)

Tapking C, Hundeshagen G, Kirchner M, Fischer S, Kneser U, Bliesener B

Извор‎: Burns. 2022;48(3):522-28.

Индекс‎: PubMed 35339324

DOI‎: 10.1016/j.burns.2022.03.002

https://pubmed.ncbi.nlm.nih.gov/35339324/ (отвара нови прозор)

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery. (отвара нови прозор)

Barua A, Rao VP, Ramesh B, Barua B, El-Shafei H.

Извор‎: J Blood Med 2011;2:131-4.

Индекс‎: PubMed 22287872

DOI‎: 10.2147/JBM.S21609

https://www.ncbi.nlm.nih.gov/pubmed/22287872 (отвара нови прозор)

The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. (отвара нови прозор)

Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, Warren B; NovoSeven Trauma Study Group.

Извор‎: Transfusion 2009;49 Suppl 5:240S-7S.

Индекс‎: PubMed 19954486

DOI‎: 10.1111/j.1537-2995.2008.01987.x

https://www.ncbi.nlm.nih.gov/pubmed/19954486 (отвара нови прозор)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (отвара нови прозор)

Fries D

Извор‎: Transfusion 2013;53 Suppl 1:91S-5S.

Индекс‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (отвара нови прозор)

A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. (отвара нови прозор)

Haan J, Scalea T

Извор‎: Am Surg 2005;71(5):414-5.

Индекс‎: PubMed 15986972

https://www.ncbi.nlm.nih.gov/pubmed/15986972 (отвара нови прозор)

Results of the control trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. (отвара нови прозор)

Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, Dimsits J, Bouillon B; CONTROL Study Group.

Извор‎: J Trauma 2010;69(3):489-500.

Индекс‎: PubMed 20838118

DOI‎: 10.1097/TA.0b013e3181edf36e

https://www.ncbi.nlm.nih.gov/pubmed/20838118 (отвара нови прозор)

Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. (отвара нови прозор)

Hsia CC, Chin-Yee IH, McAlister VC.

Извор‎: Ann Surg 2008;248(1):61-8.

Индекс‎: PubMed 18580208

DOI‎: 10.1097/SLA.0b013e318176c4ec

https://www.ncbi.nlm.nih.gov/pubmed/18580208 (отвара нови прозор)

Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases. (отвара нови прозор)

Johansson PI, Eriksen K, Alsbjørn B

Извор‎: J Trauma 2006;61(4):1016-8.

Индекс‎: PubMed 17033583

DOI‎: 10.1097/01.ta.0000239261.48022.f1

https://www.ncbi.nlm.nih.gov/pubmed/17033583 (отвара нови прозор)

Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. (отвара нови прозор)

Kandane-Rathnayake RK, Isbister JP, Zatta AJ, Aoki NJ, Cameron P, Phillips LE; Australian and New Zealand Haemostasis Registry Steering Committee

Извор‎: ANZ J Surg 2013;83(3):155-60.

Индекс‎: PubMed 23035873

DOI‎: 10.1111/j.1445-2197.2012.06285.x

https://www.ncbi.nlm.nih.gov/pubmed/23035873 (отвара нови прозор)

Recombinant factor VIIa in trauma patients with the 'triad of death.' (отвара нови прозор)

Mitra B, Cameron PA, Parr MJ, Phillips L.

Извор‎: Injury 2012;43(9):1409-14.

Индекс‎: PubMed 21345431

DOI‎: 10.1016/j.injury.2011.01.033

https://www.ncbi.nlm.nih.gov/pubmed/21345431 (отвара нови прозор)

Low-dose recombinant factor VIIa for trauma patients with coagulopathy. (отвара нови прозор)

Stein DM, Dutton RP, Hess JR, Scalea TM.

Извор‎: Injury 2008;39(9):1054-61.

Индекс‎: PubMed 18656871

DOI‎: 10.1016/j.injury.2008.03.032

https://www.ncbi.nlm.nih.gov/pubmed/18656871 (отвара нови прозор)

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (отвара нови прозор)

Tanaka KA, Waly AA, Cooper WA, Levy JH.

Извор‎: Anesthesiology 2003;98(6):1513-5.

Индекс‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 (отвара нови прозор)

Alternatives to allogeneic platelet transfusion. (отвара нови прозор)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Извор‎: Br J Haematol 2016;175(3):381-92.

Индекс‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (отвара нови прозор)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (отвара нови прозор)

Fries D

Извор‎: Transfusion 2013;53 Suppl 1:91S-5S.

Индекс‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (отвара нови прозор)

Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. (отвара нови прозор)

Kindo M, Hoang Minh T, Gerelli S, Perrier S, Meyer N, Schaeffer M, Bentz J, Announe T, Mommerot A, Collange O, Pottecher J, Cristinar M, Thiranos JC, Gros H, Mertes PM, Billaud P, Mazzucotelli JP

Извор‎: Thromb Res 2014;134(2):360-8.

Индекс‎: PubMed 24857189

DOI‎: 10.1016/j.thromres.2014.05.008

https://www.ncbi.nlm.nih.gov/pubmed/24857189 (отвара нови прозор)

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. (отвара нови прозор)

Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B

Извор‎: Br J Haematol 2013;160(2):228-36.

Индекс‎: PubMed 23151086

DOI‎: 10.1111/bjh.12118

https://www.ncbi.nlm.nih.gov/pubmed/23151086 (отвара нови прозор)

Strategies to reduce the use of blood products: a European perspective. (отвара нови прозор)

Theusinger OM, Felix C, Spahn DR.

Извор‎: Curr Opin Anaesthesiol 2012;25(1):59-65.

Индекс‎: PubMed 22113184

DOI‎: 10.1097/ACO.0b013e32834dec98

https://www.ncbi.nlm.nih.gov/pubmed/22113184 (отвара нови прозор)

Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. (отвара нови прозор)

Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E, Fochi O, Maj G, Calabrò MG, Ranucci M, Zangrillo A

Извор‎: Anesthesiology 2008;109(6):1063-76.

Индекс‎: PubMed 19034103

DOI‎: 10.1097/ALN.0b013e31818db18b

https://www.ncbi.nlm.nih.gov/pubmed/19034103 (отвара нови прозор)

Alternatives to allogeneic platelet transfusion. (отвара нови прозор)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Извор‎: Br J Haematol 2016;175(3):381-92.

Индекс‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (отвара нови прозор)

Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. (отвара нови прозор)

Svensson PJ, Bergqvist PB, Juul KV, Berntorp E

Извор‎: Blood Rev 2014;28(3):95-102.

Индекс‎: PubMed 24703870

DOI‎: 10.1016/j.blre.2014.03.001

https://www.ncbi.nlm.nih.gov/pubmed/24703870 (отвара нови прозор)

Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. (отвара нови прозор)

Alperin JB

Извор‎: JAMA 1987;258(14):1916-9.

Индекс‎: PubMed 3656602

DOI‎: 10.1001/jama.1987.03400140078028

https://www.ncbi.nlm.nih.gov/pubmed/3656602 (отвара нови прозор)

Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. (отвара нови прозор)

Crowther MA, McDonald E, Johnston M, Cook D

Извор‎: Blood Coagul Fibrinolysis 2002;13(1):49-52.

Индекс‎: PubMed 11994567

DOI‎: 10.1097/00001721-200201000-00007

https://www.ncbi.nlm.nih.gov/pubmed/11994567 (отвара нови прозор)

The use of fibrin sealant in burn operations. (отвара нови прозор)

Foster K

Извор‎: Surgery 2007;142(4 Suppl):S50-4.

Индекс‎: PubMed 18019939

DOI‎: 10.1016/j.surg.2007.06.026

https://www.ncbi.nlm.nih.gov/pubmed/18019939 (отвара нови прозор)

Use of fibrin sealant in thermal injury. (отвара нови прозор)

McGill V, Kowal-Vern A, Lee M, Greenhalgh D, Gomperts E, Bray G, Gamelli R

Извор‎: J Burn Care Rehabil 1997;18(5):429-34.

Индекс‎: PubMed 9313125

DOI‎: 10.1097/00004630-199709000-00011

https://www.ncbi.nlm.nih.gov/pubmed/9313125 (отвара нови прозор)

Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. (отвара нови прозор)

Schaden E, Kimberger O, Kraincuk P, Baron DM, Metnitz PG, Kozek-Langenecker S

Извор‎: Br J Anaesth 2012;109(3):376-81.

Индекс‎: PubMed 22719014

DOI‎: 10.1093/bja/aes186

https://www.ncbi.nlm.nih.gov/pubmed/22719014 (отвара нови прозор)

Transfusion in trauma: why and how should we change our current practice? (отвара нови прозор)

Theusinger OM, Spahn DR, Ganter MT.

Извор‎: Curr Opin Anaesthesiol 2009;22(2):305-12.

Индекс‎: PubMed 19390257

DOI‎: 10.1097/ACO.0b013e3283212c7c

https://www.ncbi.nlm.nih.gov/pubmed/19390257 (отвара нови прозор)

Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. (отвара нови прозор)

Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J

Извор‎: Health Technol Assess 2015;19(58):1-228.

Индекс‎: PubMed 26215747

DOI‎: 10.3310/hta19580

https://www.ncbi.nlm.nih.gov/pubmed/26215747 (отвара нови прозор)